Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/18536

Title: Characterisation of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development
Authors: Heathman, Thomas R.J.
Rafiq, Qasim A.
Chan, Alexander K.C.
Coopman, Karen
Nienow, Alvin W.
Kara, Bo
Hewitt, Christopher J.
Keywords: Bioprocess design
Characterization
Biomedical
Scale-up
Tissue cell culture
Human mesenchymal stem cells
Issue Date: 2016
Publisher: © The Authors. Published by Elsevier B.V.
Citation: HEATHMAN, T.R.J. et al., 2016. Characterisation of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development. Biochemical Engineering Journal, 108, pp.14-23.
Abstract: Cell-based therapies have the potential to contribute to global healthcare, whereby the use of living cells and tissues can be used as medicinal therapies. Despite this potential, many challenges remain before the full value of this emerging field can be realized. The characterization of input material for cell-based therapy bioprocesses from multiple donors is necessary to identify and understand the potential implications of input variation on process development. In this work, we have characterized bone marrow derived human mesenchymal stem cells (BM-hMSCs) from multiple donors and discussed the implications of the measurable input variation on the development of autologous and allogeneic cell-based therapy manufacturing processes. The range of cumulative population doublings across the five BM-hMSC lines over 30 days of culture was 5.93, with an 18.2% range in colony forming efficiency at the end of the culture process and a 55.1% difference in the production of interleukin-6 between these cell lines. It has been demonstrated that this variation results in a range in the process time between these donor hMSC lines for a hypothetical product of over 13 days, creating potential batch timing issues when manufacturing products from multiple patients. All BM-hMSC donor lines demonstrated conformity to the ISCT criteria but showed a difference in cell morphology. Metabolite analysis showed that hMSCs from the different donors have a range in glucose consumption of 26.98 pmol cell−1 day−1, Lactate production of 29.45 pmol cell−1 day−1 and ammonium production of 1.35 pmol cell−1 day−1, demonstrating the extent of donor variability throughout the expansion process. Measuring informative product attributes during process development will facilitate progress towards consistent manufacturing processes, a critical step in the translation cell-based therapies.
Description: This is an open access article published by Elsevier under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Sponsor: Engineering and Physical Sciences Research Council (EPSRC) [grant number: EP/F500491/1], FUJIFILM Diosynth Biotechnologies, Lonza Cologne AG and Loughborough University
Version: Published
DOI: 10.1016/j.bej.2015.06.018
URI: https://dspace.lboro.ac.uk/2134/18536
Publisher Link: http://dx.doi.org/10.1016/j.bej.2015.06.018
ISSN: 1873-295X
Appears in Collections:Published Articles (Chemical Engineering)

Files associated with this item:

File Description SizeFormat
Coopman_1-s2.0-S1369703X15300073-main.pdfPublished version1.67 MBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.